Profile data is unavailable for this security.
About the company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
- Revenue in USD (TTM)0.00
- Net income in USD-33.83m
- Incorporated1997
- Employees25.00
- LocationNuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
- Phone+44 131 248 3660
- Fax+44 131 248 3001
- Websitehttps://www.nucana.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.04m | 19.00 | -- | 0.9261 | -- | 6.82 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -10.10m | 6.05m | 5.00 | -- | 0.4868 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
Kineta Inc | 5.16m | -17.89m | 6.12m | 11.00 | -- | -- | -- | 1.19 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
4Cable TV International Inc | 758.68k | -3.14m | 6.14m | 0.00 | -- | -- | -- | 8.10 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 6.14m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Xenetic Biosciences Inc | 2.44m | -4.47m | 6.15m | 4.00 | -- | 0.7086 | -- | 2.51 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
NuCana PLC (ADR) | 0.00 | -33.83m | 6.27m | 25.00 | -- | 0.5232 | -- | -- | -302.36 | -302.36 | 0.00 | 5.66 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
Titan Pharmaceuticals Inc | 87.00k | -4.95m | 6.38m | 4.00 | -- | 1.05 | -- | 73.35 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 6.39m | 8.00 | -- | 2.32 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 6.39m | 80.00 | -- | 0.5985 | -- | 0.1242 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
Ainos Inc | 93.68k | -14.56m | 6.41m | 46.00 | -- | 0.2764 | -- | 68.42 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
BioCardia Inc | 468.00k | -10.34m | 6.44m | 16.00 | -- | -- | -- | 13.77 | -7.04 | -7.04 | 0.3132 | -1.27 | 0.0954 | -- | 4.44 | 29,250.00 | -210.81 | -107.34 | -1,190.90 | -154.17 | -- | -- | -2,208.76 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
GT Biopharma Inc | 0.00 | -9.64m | 6.45m | 2.00 | -- | 0.7773 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
Trevena Inc | 3.14m | -40.15m | 6.50m | 23.00 | -- | -- | -- | 2.07 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Holder | Shares | % Held |
---|---|---|
Acadian Asset Management LLCas of 31 Mar 2024 | 23.63k | 1.12% |
Renaissance Technologies LLCas of 31 Mar 2024 | 16.83k | 0.80% |
HRK LUNIS AGas of 30 Dec 2022 | 8.80k | 0.42% |
Citadel Securities LLCas of 31 Mar 2024 | 3.57k | 0.17% |
HRT Financial LLCas of 31 Mar 2024 | 1.34k | 0.06% |
Edmond de Rothschild (Suisse) SA (Private Banking)as of 31 Mar 2024 | 1.00k | 0.05% |
Horizon Kinetics Asset Management LLCas of 31 Mar 2024 | 779.00 | 0.04% |
Geode Capital Management LLCas of 31 Mar 2024 | 751.00 | 0.04% |
G1 Execution Services LLCas of 31 Mar 2024 | 566.00 | 0.03% |
BNP Paribas Financial Marketsas of 31 Mar 2024 | 500.00 | 0.02% |